florham

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

November 26, 2025 19:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27,…

3 weeks ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…

2 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

September 04, 2025 20:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05,…

3 months ago

HUTCHMED to Announce 2025 Half-Year Financial Results

July 03, 2025 04:30 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03,…

6 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

June 18, 2025 16:30 ET  | Source: Cellectar Biosciences, Inc. FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar…

6 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

6 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

May 30, 2025 17:30 ET  | Source: Celularity Inc. FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc.…

7 months ago